financetom
Business
financetom
/
Business
/
Kinaxis Q2 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kinaxis Q2 revenue beats estimates
Aug 6, 2025 2:51 PM

Overview

* Kinaxis ( KXSCF ) fiscal Q2 revenue grows 15% yr/yr, beating analyst expectations

* SaaS revenue rises 17%, prompting raised guidance for fiscal 2025

* Record levels achieved for profit, EPS, and adjusted EBITDA margin

Outlook

* Kinaxis ( KXSCF ) raises 2025 SaaS growth guidance to 13-15%

* Company projects 2025 total revenue of $535-550 mln

* Kinaxis ( KXSCF ) expects 2025 adjusted EBITDA margin of 23-25%

Result Drivers

* SAAS REVENUE GROWTH - SaaS revenue rose 17%, prompting an increase in SaaS growth guidance for 2025

* NEW BUSINESS WINS - Record Q2 for new business with balanced new customer wins and expansion orders, driving ARR growth of 15%

* AI ADOPTION - Early innovator customers using new generative and agentic AI capabilities, enhancing supply chain autonomy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $136.42 $133.70

Revenue mln mln (9

Analysts

)

Q2 Gross $87.53

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Kinaxis Inc ( KXSCF ) is C$225.00, about 8.1% above its August 5 closing price of C$206.76

* The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 38 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trinity Capital Provides $15 Million Growth Capital to TQA to Scale AI and Automation
Trinity Capital Provides $15 Million Growth Capital to TQA to Scale AI and Automation
Sep 9, 2025
08:34 AM EDT, 09/09/2025 (MT Newswires) -- Trinity Capital ( TRIN ) said Tuesday it has made a commitment of $15 million in growth capital to TQA, a consulting firm on agentic automation, data, and AI consulting. The company said TAQ provides advisory, implementation, and managed services to clients across North America, Europe, and Asia and serves clients in a...
Phillips 66 To Acquire Cenovus Stake In WRB Refining For $1.4 Billion Cash Deal
Phillips 66 To Acquire Cenovus Stake In WRB Refining For $1.4 Billion Cash Deal
Sep 9, 2025
Phillips 66 announced on Tuesday that it will acquire the remaining 50% stake in WRB Refining LP from Cenovus Energy Inc. ( CVE ) for $1.4 billion in cash, giving it full ownership of two U.S. refineries it has operated since 2007. The deal covers Cenovus’ share of the Wood River refinery in Roxana, Illinois, and the Borger refinery in...
Exclusive-Stablecoin issuer Figure Technologies set to upsize IPO as demand for crypto-related stocks soars, source says
Exclusive-Stablecoin issuer Figure Technologies set to upsize IPO as demand for crypto-related stocks soars, source says
Sep 9, 2025
NEW YORK (Reuters) -Stablecoin issuer Figure Technologies is increasing the size and upping the price of its initial public offering as retail investors bid up crypto-related stocks, a person familiar with direct knowledge of the matter told Reuters. The company is considering a new IPO price range of $20 - $22 a share - from $18 - $20 a share -...
Jazz Pharmaceuticals Says Modeyso Added to NCCN Guidelines for Rare Brain Cancer
Jazz Pharmaceuticals Says Modeyso Added to NCCN Guidelines for Rare Brain Cancer
Sep 9, 2025
08:34 AM EDT, 09/09/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Tuesday its drug Modeyso has been included in the National Comprehensive Cancer Network's oncology guidelines as a treatment option for pediatric and adult patients with recurrent or progressive mutant diffuse glioma. The drug received accelerated approval from the US Food and Drug Administration in August for patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved